Fibrosis is an endpoint for multiple diseases and is driven by the excessive production and deposition of collagen and other extracellular matrix proteins in tissues and organs. The increase in tissue stiffness associated with fibrosis impacts the normal functioning of tissues such as the lung, kidney and liver.
Aragen has a portfolio of in vivo fibrosis models and world class expertise to support clients in the development of anti-fibrotic therapeutic or prophylactic candidates. In hundreds of studies, over the course of more than a decade, we have evaluated the efficacy of test compounds spanning several modalities (small molecules, biologics, RNA therapeutics, exosomes etc.) on a variety of assay platforms, ultimately resulting in INDs for our clients. Our diet-induced, chemical-induced and surgical models of fibrosis, coupled with an extensive evaluation of disease biomarkers, as well as cellular and molecular mechanisms, can help drive research efforts towards finding novel therapies.
Would you like to know more about our portfolio of in vivo fibrosis models? Our dedicated team is ready to assist you to meet your needs. Reach out to us now and let us guide you towards success.
